VTYX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 116379 min ago

@ $2.33

Wydano: 14 vas. 2024 @ 16:30

Zwrot: 108.15%

Poprzedni sygnał: vas. 12 - 21:19

Poprzedni sygnał: Kupno

Zwrot: -6.99 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders...

Stats
Dzisiejszy wolumen	842 581
Średni wolumen	4.02M
Kapitalizacja rynkowa	341.92M
EPS	$0 ( 2024-03-28 )
Następna data zysków	( $-0.670 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.470
ATR14	$0.00700 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-12	Subramaniam Somu	Sell	695 339	Common Stock
2024-04-12	Nsv Partners Iii Lp	Sell	695 339	Common Stock
2024-04-02	Krueger Christopher W	Sell	1 651	Common Stock
2024-04-02	Nuss John	Sell	1 651	Common Stock
2024-04-02	Mohan Raju	Sell	4 312	Common Stock

INSIDER POWER
-9.41
Last 100 transactions
Buy: 2 083 814 \| Sell: 2 354 020

Wolumen Korelacja

Długi: -0.57 (weak negative)

Krótki: -0.25 (neutral)

Signal:(23.935) Neutral

Ventyx Biosciences, Inc. Korelacja

10 Najbardziej pozytywne korelacje
SVRA	0.94
SY	0.936
IDCC	0.93
OVID	0.929
NVCN	0.929
QRTEA	0.927
HURC	0.926
OVLY	0.919
GPACU	0.919
VBOC	0.918

10 Najbardziej negatywne korelacje
NAKD	-0.93
PRPH	-0.91
ORPH	-0.903
CHKEL	-0.902
CSSEP	-0.902
PROC	-0.9
ALXO	-0.898
HCAQ	-0.897
SGLY	-0.895
TRIT	-0.895

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ventyx Biosciences, Inc. Korelacja - Waluta/Towar

0.56
( weak )

0.55
( weak )

0.00
( neutral )

0.58
( weak )

-0.34
( neutral )

Ventyx Biosciences, Inc. Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-941 000 (0.00 %)
EPS:	$-3.30

FY	2023
Przychody:	$0
Zysk brutto:	$-941 000 (0.00 %)
EPS:	$-3.30

FY	2022
Przychody:	$0
Zysk brutto:	$-470 000 (0.00 %)
EPS:	$-2.06

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-6.65

Financial Reports:

No articles found.

Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

Aktualne aktualizacje dla Ventyx Biosciences, Inc. [VTYX]

Upcoming Earnings Alert